Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Olema Pharmaceuticals ( (OLMA) ) has shared an update.
On April 27, 2026, Olema Pharmaceuticals entered into a seven-year lease with KR Oyster Point II, LLC for about 38,176 square feet of office space across the fourth and fifth floors of a building at Oyster Point, with plans to relocate its corporate headquarters there by December 2026. The new lease will replace existing San Francisco office and lab leases expiring between December 2026 and January 2027 and includes options for early termination with a fee, a five-year extension, and a right of first offer to expand into additional fifth- and sixth-floor space.
Under the agreement, the landlord will complete specified build-out work at its own cost before Olema takes possession of the premises, and the company must provide a cash security deposit of $427,546.80. Total base rent during the initial term, net of abatements, is set at $12,361,188.00 for Phase I, expected to commence around September 15, 2026, and $6,145,463.76 for Phase II, expected to commence around December 1, 2026, with Olema also responsible for its share of operating expenses, taxes, and other customary lease obligations.
The most recent analyst rating on (OLMA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.
Spark’s Take on OLMA Stock
According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.
Overall score is pulled down primarily by persistent, widening losses and accelerating cash burn, plus a clearly bearish technical setup (price below key moving averages and negative MACD). The main offset is a strong, low-leverage balance sheet that provides financial flexibility, but valuation is not supportive due to negative earnings and no dividend.
To see Spark’s full report on OLMA stock, click here.
More about Olema Pharmaceuticals
Olema Pharmaceuticals, Inc. is a biopharmaceutical company that operates corporate office and laboratory facilities in San Francisco, focusing on research and development activities in its sector. The company maintains leased office and lab spaces and is now repositioning its physical footprint with a new headquarters move within the Bay Area market.
Average Trading Volume: 1,557,894
Technical Sentiment Signal: Hold
Current Market Cap: $1.26B
See more insights into OLMA stock on TipRanks’ Stock Analysis page.